BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23836530)

  • 1. Prophylaxis for latent tuberculosis infection prior to anti–tumor necrosis factor therapy in low-risk elderly patients with rheumatoid arthritis: a decision analysis.
    Hazlewood GS; Naimark D; Gardam M; Bykerk V; Bombardier C
    Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1722-31. PubMed ID: 23836530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework.
    Sadatsafavi M; Marra C; Marra F; Moran O; FitzGerald JM; Lynd L
    Value Health; 2013; 16(1):66-75. PubMed ID: 23337217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area.
    Bonfiglioli KR; Ribeiro AC; Moraes JC; Saad CG; Souza FH; Calich AL; Bonfa E; Laurindo IM
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):905-11. PubMed ID: 25199003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.
    Mariette X; Baron G; Tubach F; Lioté F; Combe B; Miceli-Richard C; Flipo RM; Goupille P; Allez M; Salmon D; Emilie D; Carcelain G; Ravaud P
    Ann Rheum Dis; 2012 Nov; 71(11):1783-90. PubMed ID: 22258485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of tuberculin skin test for isoniazid prophylaxis in BCG vaccinated children who are using anti-TNF agents for rheumatologic diseases.
    Kilinc AA; Onal P; Oztosun B; Yildiz M; Adrovic A; Sahin S; Barut K; Cokugras H; Kasapcopur O
    Pediatr Pulmonol; 2020 Oct; 55(10):2689-2696. PubMed ID: 32776324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.
    Ponce de Leon D; Acevedo-Vasquez E; Alvizuri S; Gutierrez C; Cucho M; Alfaro J; Perich R; Sanchez-Torres A; Pastor C; Sanchez-Schwartz C; Medina M; Gamboa R; Ugarte M
    J Rheumatol; 2008 May; 35(5):776-81. PubMed ID: 18398944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
    Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
    J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis.
    Sichletidis L; Settas L; Spyratos D; Chloros D; Patakas D
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1127-32. PubMed ID: 17044206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
    Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
    Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?
    Akyuz F; Cavus B; Iliaz R; Soyer OM; Ormeci A; Evirgen S; Onder S; Koksalan K; Keskin M; Karaca C; Demir K; Gulluoglu M; Cagatay T; Besisik F; Kaymakoglu S
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):777-780. PubMed ID: 30964811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and efficacy of isoniazid prophylaxis for latent tuberculosis in HIV-infected clients patients in Thailand.
    Khongphatthanayothin M; Avihingsanon A; Teeratakulpisarn N; Phanuphak N; Buajoom R; Suwanmala P; Phanuphak P
    AIDS Res Hum Retroviruses; 2012 Mar; 28(3):270-5. PubMed ID: 21899431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
    Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
    Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis.
    Kurt OK; Kurt B; Talay F; Tug T; Soy M; Bes C; Hayran M
    Wien Klin Wochenschr; 2013 Oct; 125(19-20):616-20. PubMed ID: 24061693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy.
    Sung YK; Cho SK; Kim D; Won S; Choi CB; Kim TH; Jun JB; Yoo DH; Bae SC
    Korean J Intern Med; 2018 Sep; 33(5):1016-1024. PubMed ID: 28288508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy.
    Chen DY; Shen GH; Hsieh TY; Hsieh CW; Lan JL
    Arthritis Rheum; 2008 Jun; 59(6):800-6. PubMed ID: 18512714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis.
    Inanc N; Aydin SZ; Karakurt S; Atagunduz P; Yavuz S; Direskeneli H
    J Rheumatol; 2009 Dec; 36(12):2675-81. PubMed ID: 19918035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unaffected reaction level in tuberculin skin test by long-term therapy with tumor necrosis factor inhibitors for rheumatoid arthritis.
    Yamamoto S; Nagatani K; Sato T; Iwamoto M; Takatori S; Minota S
    Int J Rheum Dis; 2017 May; 20(5):584-588. PubMed ID: 28524434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay.
    Chen DY; Shen GH; Chen YM; Chen HH; Hsieh CW; Lan JL
    Ann Rheum Dis; 2012 Feb; 71(2):231-7. PubMed ID: 22021896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The clinical application of quantiferon TB-2G: its usefulness and limitations].
    Sato S; Nagai H
    Kekkaku; 2011 Feb; 86(2):101-12. PubMed ID: 21404654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients.
    Sánchez-Moya AI; Dauden E
    J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):730-3. PubMed ID: 21564322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.